New drug duo targets Tough-to-Treat breast cancer
NCT ID NCT03090165
Summary
This study is testing whether combining two existing drugs—ribociclib and bicalutamide—can help control advanced triple-negative breast cancer that has a specific marker called the androgen receptor. The goal is to see if the combination is safe and can slow or shrink tumors. The study is for adults whose cancer has spread or cannot be removed by surgery and who have had up to three prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Michigan State University
Lansing, Michigan, 48910, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.